Gene therapy plus radiation shows promise in prostate cancer trial
Disease control
Recruiting now
This study tests a new gene therapy (aglatimagene besadenovec) combined with standard radiation in 45 men with intermediate-risk prostate cancer. The goal is to see how the therapy spreads in the body and whether it boosts the immune system against the cancer. Participants receiv…
Phase: PHASE2 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC